Patents by Inventor Michael Gordon Joyce

Michael Gordon Joyce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11027007
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: June 8, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
  • Patent number: 10960070
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: March 30, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Patent number: 10961283
    Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: March 30, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington
  • Patent number: 10858400
    Abstract: Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: December 8, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Barney Graham, Jason McLellan, Man Chen, Baoshan Zhang, Tongqing Zhou, Michael Gordon Joyce, Yongping Yang
  • Patent number: 10759846
    Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: September 1, 2020
    Assignee: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola
  • Publication number: 20200230229
    Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 23, 2020
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
    Inventors: Peter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Michael Gordon Joyce, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong, Yongping Yang
  • Publication number: 20200190168
    Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and to methods of using those compositions of matter for the same. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.
    Type: Application
    Filed: April 25, 2018
    Publication date: June 18, 2020
    Inventors: Wei BU, Masaru KANEKIYO, Michael Gordon JOYCE, Jeffrey I. COHEN
  • Publication number: 20200061185
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 27, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Publication number: 20200009243
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 9, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
  • Publication number: 20190389915
    Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 26, 2019
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, John Mascola, Baoshan Zhang, Cheng Cheng, Mallika Sastry
  • Publication number: 20190330279
    Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 31, 2019
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Service
    Inventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Rita Chen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Paul Thomas, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington, Kizzmekia Corbett
  • Patent number: 10420834
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: September 24, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones
  • Patent number: 10400015
    Abstract: HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: September 3, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Marie Pancera, Tongqing Zhou, Ivelin Georgiev, Michael Gordon Joyce, Priyamvada Acharya, Jason Gorman, Yongping Yang, Aliaksandr Druz, Guillaume Stewart-Jones, Rita Chen, Gwo-Yu Chuang, Ulrich Baxa, John Mascola, Rebecca Lynch, Baoshan Zhang, Cheng Cheng
  • Publication number: 20190256579
    Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 22, 2019
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola
  • Patent number: 10301377
    Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: May 28, 2019
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola
  • Publication number: 20190112340
    Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.
    Type: Application
    Filed: March 29, 2017
    Publication date: April 18, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
  • Publication number: 20180319846
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Application
    Filed: July 2, 2018
    Publication date: November 8, 2018
    Applicant: The United States of America,as represented by the Secretary,Department of Helath and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Publication number: 20180244756
    Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.
    Type: Application
    Filed: February 24, 2016
    Publication date: August 30, 2018
    Applicant: The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola
  • Patent number: 10017543
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 10, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Publication number: 20180008697
    Abstract: Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.
    Type: Application
    Filed: December 24, 2015
    Publication date: January 11, 2018
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Institute for Research in Biomedicine
    Inventors: Peter Kwong, Michael Gordon Joyce, Baoshan Zhang, Yongping Yang, Peter Collins, Ursula Buchholz, Davide Corti, Antonio Lanzavecchia, Guillaume Stewart-Jones